Home » Posts tagged with » Celgene
EC approves Reblozyl for transfusion-dependent anemia in adults

EC approves Reblozyl for transfusion-dependent anemia in adults

Bristol Myers Squibb and Acceleron Pharma have secured approval from the European Commission (EC) for their jointly developed erythroid maturation agent Reblozyl (luspatercept) for the treatment of transfusion-dependent anemia in adult patients. The approval of Reblozyl is for transfusion-dependent anemia caused by very low-, low- and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had […]

Bristol-Myers Squibb wraps up $74bn acquisition of Celgene

Bristol-Myers Squibb has wrapped up its $74 billion acquisition of Celgene having got regulatory approval from all government authorities necessary for closing the merger agreement along with approvals from stockholders of the two companies. Celgene has now become a fully-owned subsidiary of Bristol-Myers Squibb and as per the merger terms, shareholders of the former have […]

Continue reading …
FTC clears decks for Bristol-Myers Squibb acquisition of Celgene

Bristol-Myers Squibb acquisition of Celgene : US pharma giant Bristol-Myers Squibb said that the US Federal Trade Commission (FTC) has given its clearance for its previously announced $74 billion acquisition of American biotech company Celgene. The FTC has accepted the proposed consent order regarding the pending merger of Bristol-Myers Squibb and Celgene, thereby allowing the […]

Continue reading …
Celgene, Acceleron bag Reblozyl FDA approval for anemia in beta thalassemia

Reblozyl FDA approval : Celgene and Acceleron Pharma have bagged approval from the US Food and Drug Administration (FDA) for Reblozyl (luspatercept-aamt) for the treatment of anemia associated with beta thalassemia in adults who need regular red blood cell (RBC) transfusions. Reblozyl is now the first and only erythroid maturation agent to be approved by […]

Continue reading …
Amgen to acquire Celgene psoriasis drug Otezla for $13.4bn

Amgen acquisition of Otezla : Amgen has agreed to acquire global rights to Celgene’s psoriasis drug Otezla (apremilast) for $13.4 billion, which includes $2.2 billion in expected future cash tax benefits. The deal is being executed to pave way for regulatory approval for the previously announced Bristol-Myers Squibb acquisition of Celgene in a deal worth […]

Continue reading …
Celgene bags Inrebic FDA approval for myelofibrosis

Inrebic FDA approval : Celgene’s subsidiary Impact Biomedicines, has bagged approval for its oral kinase inhibitor Inrebic (fedratinib) capsules from the US Food and Drug Administration (FDA) for the treatment of certain types of myelofibrosis, a rare bone marrow cancer. Fedratinib FDA approval is for the treatment of adult patients with intermediate-2 or high-risk primary […]

Continue reading …
Celgene bags Otezla FDA approval for oral ulcers in Behcet’s Disease

Otezla FDA approval : US biotech company Celgene has bagged approval from the US Food and Drug Administration (FDA) for Otezla (apremilast) for the treatment of oral ulcers associated with Behcet’s Disease in adults. The approved dosage of the oral, selective inhibitor of phosphodiesterase 4 (PDE4) is 30mg twice daily. According to Celgene, Otezla is […]

Continue reading …
US biotech company Celgene to be acquired by Bristol-Myers Squibb for $74bn

Bristol-Myers Squibb acquisition of Celgene : US biotech company Celgene has agreed to be acquired by Bristol-Myers Squibb in a stock and cash deal worth about $74 billion, as per the latest pharma acquisition news. The merger of the two US pharma companies will form a specialty biopharma company focused on developing high-value innovative medicines […]

Continue reading …